BACKGROUND/AIMS: The differentiation of hepatocellular carcinoma from benign liver diseases in hepatitis B virus carriers by imaging studies based upon morphological aspects can be difficult. METHODOLOGY: FDG-PET (18F-2-deoxyglucose positron emission tomographies) were performed in 48 hepatitis B virus carriers to detect hepatocellular carcinoma and differentiate other benign liver diseases. In each patient, the focal liver lesion was visible by ultrasound and an elevated serum alpha-fetoprotein level was noted. Definite diagnosis was established after ultrasound-guided liver biopsy followed by histopathological examination. RESULTS: The histopathological examination revealed hepatocellular carcinoma in 36 patients and benign liver diseases in the remaining 12 patients. Twenty of 36 hepatocellular carcinomas were detectable by FDG-PET and none of 12 benign liver diseases were visualized by FDG-PET. The detection sensitivity of FDG-PET was not related to the echogenicity and size of hepatocellular carcinoma. CONCLUSIONS: FDG-PET is not sensitive to but is more specific than ultrasound and serum alpha-feto-protein level to detect hepatocellular carcinoma and differentiate from other benign liver diseases in hepatitis B virus carriers.
BACKGROUND/AIMS: The differentiation of hepatocellular carcinoma from benign liver diseases in hepatitis B virus carriers by imaging studies based upon morphological aspects can be difficult. METHODOLOGY: FDG-PET (18F-2-deoxyglucose positron emission tomographies) were performed in 48 hepatitis B virus carriers to detect hepatocellular carcinoma and differentiate other benign liver diseases. In each patient, the focal liver lesion was visible by ultrasound and an elevated serum alpha-fetoprotein level was noted. Definite diagnosis was established after ultrasound-guided liver biopsy followed by histopathological examination. RESULTS: The histopathological examination revealed hepatocellular carcinoma in 36 patients and benign liver diseases in the remaining 12 patients. Twenty of 36 hepatocellular carcinomas were detectable by FDG-PET and none of 12 benign liver diseases were visualized by FDG-PET. The detection sensitivity of FDG-PET was not related to the echogenicity and size of hepatocellular carcinoma. CONCLUSIONS: FDG-PET is not sensitive to but is more specific than ultrasound and serum alpha-feto-protein level to detect hepatocellular carcinoma and differentiate from other benign liver diseases in hepatitis B virus carriers.
Authors: Ji Eun Lee; Jae Young Jang; Soung Won Jeong; Sae Hwan Lee; Sang Gyune Kim; Sang-Woo Cha; Young Seok Kim; Young Deok Cho; Hong Soo Kim; Boo Sung Kim; So Young Jin; Deuk Lin Choi Journal: World J Gastroenterol Date: 2012-06-21 Impact factor: 5.742
Authors: Rania Refaat; Mohammad Abd Alkhalik Basha; Mohammed Sobhi Hassan; Rasha S Hussein; Ahmed A El Sammak; Dena Abd El Aziz El Sammak; Mohamed Hesham Saleh Radwan; Nahla M Awad; Somaia A Saad El-Din; Engi Elkholy; Dina R D Ibrahim; Shereen A Saleh; Iman F Montasser; Hany Said Journal: Eur Radiol Date: 2018-06-12 Impact factor: 5.315
Authors: Nicolas Salem; Gregory T MacLennan; Yu Kuang; Paul W Anderson; Steve J Schomisch; Ilia A Tochkov; Bud C Tennant; Zhenghong Lee Journal: Mol Imaging Biol Date: 2007 May-Jun Impact factor: 3.484
Authors: Min Jin Kim; Young Seok Kim; Youn Hee Cho; Hee Yoon Jang; Jeong-Yeop Song; Sae Hwan Lee; Soung Won Jeong; Sang Gyune Kim; Jae Young Jang; Hong Su Kim; Boo Sung Kim; Won Hyung Lee; Jung Mi Park; Jae Myung Lee; Min Hee Lee; Deuk Lin Choi Journal: Korean J Intern Med Date: 2015-04-29 Impact factor: 2.884